Pre- and post-transplant monitoring of soluble CD30 levels as predictor of acute renal allograft rejection

Transplant Immunology

Volumn 17, Issue 4, 2007, Pages 278-282

  Wang, Dong ^a,b   Wu, Guo Jun ^b   Wu, Wei Zhen ^a   Yang, Shun Liang ^a   Chen, Jin Hua ^a   Wang, He ^b   Lin, Wen Hong ^a   Wang, Qing Hua ^a   Zeng, Zhang Xin ^a   Tan, Jian Ming ^a  

^a FUZHOU GENERAL HOSPITAL   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Acute rejection; ELISA; Immunosuppressive regimens; Renal transplantation; Soluble CD30

Indexed keywords

CD30 ANTIGEN;

ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTIGENS, CD30; COHORT STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 34247643802     PISSN: 09663274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trim.2007.02.001     Document Type: Article

References (23)

1. Gebel H.M., Bray R.A., and Nickerson P. Pre-transplant assessment of donor-reactive, HLA-specific antibodies in renal transplantation: contraindication vs. risk. Am J Transplant 3 12 (2003) 1488-1500
2. Banham A.H., Powrie F.M., and Suri-Payer E. FOXP3+ regulatory T cells: current controversies and future perspectives. Eur J Immunol 36 11 (2006) 2832-2836
3. Zeevi A., Britz J.A., Bentlejewski C.A., Guaspari D., Tong W., Bond G., et al. Monitoring immune function during tacrolimus tapering in small bowel transplant recipients. Transpl Immunol 15 1 (2005) 17-24
4. Smith C.A., Gruss H.J., Davis T., Anderson D., Farrah T., Baker E., et al. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73 7 (1993) 1349-1360
5. Tarkowski M. Expression and a role of CD30 in regulation of T-cell activity. Curr Opin Hematol 10 4 (2003) 267-271
6. Kennedy M.K., Willis C.R., and Armitage R.J. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118 2 (2006) 143-152
7. Susal C., Pelzl S., Dohler B., and Opelz G. Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30. J Am Soc Nephrol 13 6 (2002) 1650-1656
8. Pelzl S., Opelz G., Daniel V., Wiesel M., and Susal C. Evaluation of posttransplantation soluble CD30 for diagnosis of acute renal allograft rejection. Transplantation 75 3 (2003) 421-423
9. Dong W., Shunliang Y., Weizhen W., Qinghua W., Zhangxin Z., Jianming T., et al. Prediction of acute renal allograft rejection in early post-transplantation period by soluble CD30. Transpl Immunol 16 1 (2006) 41-45
10. Slavcev A., Lacha J., Honsova E., Sajdlova H., Lodererova A., Vitko S., et al. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection. Transpl Immunol 14 2 (2005) 117-121
11. Racusen L.C., Solez K., Colvin R.B., Bonsib S.M., Castro M.C., Cavallo T., et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 55 2 (Feb 1999) 713-723
12. Pelzl S., Opelz G., Wiesel M., Schnulle P., Schonemann C., Dohler B., et al. Soluble CD30 as a predictor of kidney graft outcome. Transplantation 73 1 (2002) 3-6
13. Ayed K., Abdallah T.B., Bardi R., Abderrahim E., and Kheder A. Plasma levels of soluble CD30 in kidney graft recipients as predictors of acute allograft rejection. Transplant Proc 38 7 (2006) 2300-2302
14. Vaidya S., Partlow D., Barnes T., Thomas P., and Gugliuzza K. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies. Clin Transplant 20 4 (2006) 461-464
15. Kim K.H., Oh E.J., Jung E.S., Park Y.J., Choi J.Y., Kim D.G., et al. Evaluation of pre-and posttransplantation serum interferon-gamma and soluble CD30 for predicting liver allograft rejection. Transplant Proc 38 5 (2006) 1429-1431
16. Sengul S., Keven K., Gormez U., Kutlay S., Erturk S., and Erbay B. Identification of patients at risk of acute rejection by pretransplantation and posttransplantation monitoring of soluble CD30 levels in kidney transplantation. Transplantation 81 8 (2006) 1216-1219
17. Rajakariar R., Jivanji N., Varagunam M., Rafiq M., Gupta A., Sheaff M., et al. High pre-transplant soluble CD30 levels are predictive of the grade of rejection. Am J Transplant 5 8 (2005) 1922-1925
18. Cinti P., Pretagostini R., Arpino A., Tamburro M.L., Mengasini S., Lattanzi R., et al. Evaluation of pretransplant immunologic status in kidney-transplant recipients by panel reactive antibody and soluble CD30 determinations. Transplantation 79 9 (2005) 1154-1156
19. Barbano G., Cappa F., Prigione I., Pistoia V., Cohen A., Chiesa S., et al. Plasma levels of soluble CD30 are increased in children with chronic renal failure and with primary growth deficiency and decrease during treatment with recombination human growth hormone. Nephrol Dial Transplant 16 9 (2001) 1807-1813
20. Pellegrini P., Berghella A.M., Contasta I., and Adorno D. CD30 antigen: not a physiological marker for TH2 cells but an important costimulator molecule in the regulation of the balance between TH1/TH2 response. Transpl Immunol 12 1 (2003) 49-61
21. Nakamura T., Lee R.K., Nam S.Y., Al-Ramadi B.K., Koni P.A., Bottomly K., et al. Reciprocal regulation of CD30 expression on CD4+ T cells by IL-4 and IFN-gamma. J Immunol 158 5 (1997) 2090-2098
22. Bowen M.A., Lee R.K., Miragliotta G., Nam S.Y., and Podack E.R. Structure and expression of murine CD30 and its role in cytokine production. J Immunol 156 2 (1996) 442-449
23. Weimer R., Susal C., Yildiz S., Staak A., Pelzl S., Renner F., et al. Post-transplant sCD30 and neopterin as predictors of chronic allograft nephropathy: impact of different immunosuppressive regimens. Am J Transplant 6 8 (2006) 1865-1874